---
schema_version: "secwatch.filing_event.v1"
accession: "0001585364-24-000066"
form_type: "8-K"
ticker: "PRGO"
cik: "0001585364"
company_name: "PERRIGO Co plc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:29:03.287345+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Perrigo Reports Q1 2024 Adjusted EPS of $0.29, Above Projection; Net Sales Down 8.4%

## Summary
- Q1 net sales $1.1B, down 8.4% vs prior year; organic net sales declined 7.0% due to infant formula and SKU prioritization actions.
- Adjusted diluted EPS of $0.29, $0.06 ahead of projection primarily from infant formula shipment timing; down from $0.45 YoY.
- Reaffirms FY2024 outlook: organic sales growth 1%-3%, adjusted EPS range $2.50-$2.65, interest expense ~$180M.
- Infant formula impacted adjusted gross margin by -280 bps and adjusted EPS by -$0.30 in the quarter.
- Svend Andersen, EVP & President CSCI, to retire; Roberto Khoury appointed as successor effective August 1, 2024.

## SEC filing metadata
- accession: 0001585364-24-000066
- form_type: 8-K
- ticker: PRGO
- cik: 0001585364
- company_name: PERRIGO Co plc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/0001585364-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/prgo-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001585364-24-000066
- JSON: https://secwatch.observer/filing/0001585364-24-000066.json
- Plain text: https://secwatch.observer/filing/0001585364-24-000066.txt

## Key facts
- Earnings Releases
  PERRIGO Co plc reported first quarter ended March 30, 2024 results: revenue $1.1 billion, EPS $0.03. Guidance reaffirmed.
  - Period: first quarter ended March 30, 2024
  - Revenue: $1.1 billion
  - EPS: $0.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: Business Recently Announced Plan to Divest HRA Rare Diseases Business; Expects to Redeploy Proceeds for Debt Paydown First Quarter 2024 Highlights: • First quarter net sales of $1.1 billion declined 8.4% versus the prior year quarter. First quarter organic 1 net sales decreased 7.0%, due primarily to 1) -4.3 percentage points impact due to lower net sales in infant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/0001585364-24-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.